NEW YORK ( TheDeal) -- Depomed (DEPO) said it will consider a revised unsolicited bid from Horizon Pharma (HZNP) - Get Report but effectively rejected the $2 billion offer calling it a purported and conditional increase in price. 


Depomed, a specialty pharmaceutical company focused on pain and neurology medications, in April acquired the diabetes-related pain drug Nucynta from a subsidiary of Johnson & Johnson (JNJ) - Get Report for $1 billion. Nucynta is marketed and adds to the pain portfolio of Depomed and its drug delivery technology. Depomed says it is in the midst of a transformation driven in part by the addition of Nucynta and is confident in the direction the company.

Read more from:

Image placeholder title

TST Recommends